Breaking News Instant updates and real-time market news.

LULU

Lululemon

$234.79

-1.14 (-0.48%)

, LCI

Lannett

$8.27

0.03 (0.36%)

09:20
01/13/20
01/13
09:20
01/13/20
09:20

Fly Intel: Pre-market Movers

HIGHER: Lululemon (LULU), up 2% after raising its Q4 EPS outlook... Lannett (LCI), up 7% after announcing FDA approval of its Cocaine Hydrochloride Nasal Solution new drug application... Wesco (WCC), up 3% after announcing a definitive merger agreement under which the company will acquire Anixter (AXE) in a transaction valued at approximately $4.5B... TerraForm Power (TERP), up 9% after announcing Brookfield Renewable Partners (BEP) has made a non-binding, all-share proposal to acquire the outstanding Class A common shares of the company, other than the 62% owned by Brookfield Renewable and its affiliates... At Home Group (HOME), up 13% after announcing Q4 sales will be at the higher end of the previously guided range... J.Jill (JILL), up 18% after raising its Q4 EPS view. LOWER: Abiomed (ABMD), down 11% after reporting preliminary Q3 revenue... Exact sciences (EXAS), down 6% after reporting preliminary Q4 revenue .. Check Point (CHKP), down 2% after Morgan Stanley analyst Keith Weiss downgraded shares to Underweight from Equal Weight with a price target of $106, down from $115.

LULU

Lululemon

$234.79

-1.14 (-0.48%)

LCI

Lannett

$8.27

0.03 (0.36%)

WCC

Wesco

$58.09

-0.425 (-0.73%)

AXE

Anixter

$98.77

-0.02 (-0.02%)

TERP

TerraForm Power

$15.60

0.085 (0.55%)

BEP

Brookfield Renewable

$48.04

-0.45 (-0.93%)

HOME

At Home Group

$5.09

-0.095 (-1.83%)

JILL

J.Jill

$1.38

-0.01 (-0.72%)

ABMD

Abiomed

$188.93

5.2 (2.83%)

EXAS

Exact Sciences

$104.60

1 (0.97%)

CHKP

Check Point

$112.55

0.83 (0.74%)

  • 13

    Jan

  • 13

    Jan

  • 13

    Jan

  • 13

    Jan

  • 13

    Jan

  • 13

    Jan

  • 13

    Jan

  • 13

    Jan

  • 14

    Jan

  • 22

    Jan

  • 30

    Jan

  • 03

    Feb

  • 04

    Feb

  • 06

    Feb

  • 06

    Feb

  • 13

    Feb

  • 25

    Feb

LULU Lululemon
$234.79

-1.14 (-0.48%)

12/12/19
MKMP
12/12/19
NO CHANGE
Target $258
MKMP
Buy
Lululemon price target raised to $258 from $255 at MKM Partners
MKM Partners analyst Roxanne Meyer raised her price target on Lululemon to $258 and kept her Buy rating after its "solid" Q3 comps and gross margins while demonstrating "momentum" heading into Q3. The analyst adds that while a "tad short" of the high end of expectations, the 17% constant currency same store sales gain was "exceptional". Meyer further notes that the sustainability of Lululemon's momentum should remain intact given that sales rose across its channels, geographies, and gender products.
12/12/19
RBCM
12/12/19
NO CHANGE
Target $250
RBCM
Outperform
Lululemon remains 'bright spot' in consumer retail, says RBC Capital
RBC Capital analyst Kate Fitzsimons keeps her Outperform rating and $250 price target on Lululemon after its Q3 results, saying the 29% earnings growth, 17% constant-currency comps growth, and 120bp product margin expansion showcase the company as a "bright spot in consumer". The analyst believes that Lululemon can sustain its comps and earnings growth upside into Q4, with potential for multiple expansion coming from the management's innovation and engagement strategies.
01/07/20
WEDB
01/07/20
NO CHANGE
Target $235
WEDB
Neutral
Lululemon price target raised to $235 from $225 at Wedbush
Wedbush analyst Jen Redding raised her price target for Lululemon to $235 from $225 as she expects the company to beat and raise guidance on its Holiday Sales report expected early next week, preceding investor meetings at the 2020 ICR Conference in Orlando, FL. The analyst has a Neutral rating on the shares.
12/13/19
DADA
12/13/19
NO CHANGE
Target $220
DADA
Neutral
Lululemon price target raised to $220 from $185 at DA Davidson
DA Davidson analyst John Morris raised his price target on Lululemon to $220 after its Q3 earnings beat and "solid" 23% revenue growth that was driven by positive traffic in the company's physical and digital channels. The analyst is keeping his Neutral rating however, noting that company will be lapping tough compares of 17% and 16% comps in Q4 and Q1 and also stating that the guide-down in Q4 margins suggests that Lululemon is "not immune to holiday pressures".
LCI Lannett
$8.27

0.03 (0.36%)

03/19/19
RHCO
03/19/19
INITIATION
Target $9
RHCO
Hold
Lannett initiated with a Hold at SunTrust
SunTrust analyst Gregg Gilbert started Lannett with a Hold rating and $9 price target. The analyst says that while the stock's most important overhang has been removed with the loss of levothyroxine, he sees the risk/reward as relatively balanced at current share levels.
05/13/19
WELS
05/13/19
NO CHANGE
WELS
Lawsuit against Teva, others to hit generic drug stocks, says Wells Fargo
Wells Fargo analyst David Maris believes the lawsuit by 44 states against 20 generic drugmakers will weigh on generic drug stocks this week and remain an "overhang issue for some time." Actual penalties and damages are impossible to calculate, but could be material, Maris tells investors in a research note. The analyst spoke to the Connecticut attorney general's office this morning and learned they are preparing for trial in these cases. Language the attorney general has used, such as "unprecedented" and his desire to clawback all gains from collusion, should be indicative of the states' intent, Maris writes. He believes that for a sector that is generally highly levered, and with some companies named already facing an overhang from opioid litigation like Teva (TEVA), this is "especially unwelcome news."
09/18/19
RHCO
09/18/19
NO CHANGE
Target $14
RHCO
Hold
Lannett price target raised to $14 from $10 at SunTrust
SunTrust analyst Gregg Gilbert raised his price target on Lannett (LCI) to $14, adjusting his model to reflect its potentially significant opportunity with the recent launch of posaconazole - a generic version of Merck's (MRK) Noxafil. The analyst notes that he now models sales and EBITDA at the higher end of the company's FY20 targets while also raising his FY20 EPS view by 19c to $1.33. Gilbert still keeps his Hold rating on the stock, citing the uncertainty around Lannett's capital structure and limited pipeline visibility as well as the challenging environment for generics.
08/29/19
RHCO
08/29/19
NO CHANGE
Target $10
RHCO
Hold
Lannett price target raised to $10 from $7 at SunTrust
SunTrust analyst Gregg Gilbert raised his price target on Lannett to $10 after its Q4 earnings beat and the expansion of its gross margins. The analyst says the company is "making solid progress" in diversifying its business and positioning for growth beyond the Levothyroxine trough, but keeps his Hold rating to reflect the uncertainty around its capital structure and the "challenging" environment in generic drugs.
WCC Wesco
$58.09

-0.425 (-0.73%)

01/09/20
JEFF
01/09/20
NO CHANGE
Target $66
JEFF
Hold
Wesco in 'do-or-die situation' with Anixter bidding war, says Jefferies
Jefferies analyst Hamzah Mazari believes Wesco (WCC) is in "a do-or-die situation" if its bidding war with Clayton, Dubilier & Rice for Anixter International (AXE) is lost, as the analyst believes Wesco shares are likely to retrace to the $50 level if its takeover attempt is thwarted. Mazari thinks the bidding war likely continues and expects CD&R to come back within the next 5 days with a new bid, adding that the ability to lever up debt should allow the company to offer $100 per share in cash for Anixter. Mazari has a Hold rating and $66 price target on Wesco shares.
01/07/20
OPCO
01/07/20
UPGRADE
OPCO
Outperform
Wesco upgraded to Outperform from Perform at Oppenheimer
Oppenheimer upgraded Wesco to Outperform from Perform.
01/07/20
OPCO
01/07/20
UPGRADE
Target $74
OPCO
Outperform
Oppenheimer upgrades Wesco to Outperform, sees 'even odds' for Anixter deal
Oppenheimer analyst Christopher Glynn upgraded Wesco (WCC) to Outperform from Perform with a $74 price target as he sees "even odds" that that the company can achieve a winning transaction proposal to land Anixter (AXE). His analysis uses an assumed $100 per share price for Anixter and assumes $150M synergies realized by 2023, though he notes his $74 price target only weights a transaction scenario at 50% and gives a 50% weighting to no deal. Given Wesco strategic rationale and domain expertise, Glynn thinks Anixter's board must increasingly consider its proposal and he thinks it is unclear how CD&R's debt funding commitments might scale at higher bid levels, the analyst added.
01/07/20
KEYB
01/07/20
NO CHANGE
KEYB
NN, Inc. could 'benefit the most' from strategic divestiture, says KeyBanc
Against a backdrop of tepid macro data and geopolitical uncertainty, KeyBanc analyst Steve Barger expects relatively weak organic growth in early 2020. As such, the analyst thinks companies will look to drive inorganic growth via acquisitions, or conversely right-size portfolios and balance sheets via divestitures. Broadly, he views Applied Industrial Technologies (AIT), Ametek (AME), Kaman (KAMN), Timken (TKR), TriMas (TRS), and Wesco (WCC) as actively seeking acquisitions, and thinks NN, Inc. (NNBR) could benefit the most from a strategic divestiture.
AXE Anixter
$98.77

-0.02 (-0.02%)

01/06/20
LBOW
01/06/20
UPGRADE
Target $70
LBOW
Buy
Longbow upgrades Wesco to Buy amid battle to acquire Anixter
Longbow analyst Chris Dankert upgraded Wesco (WCC) to Buy from Neutral with a $70 price target. The analyst believes the battle to acquire Anixter (AXE) between Wesco and Clayton, Dubilier & Rice will ultimately serve as a positive catalyst for Wesco shares. Should Wesco succeed in acquiring Anixter, operational synergies would drive "substantial" earnings accretion while also easing its competitive pricing pressure, Dankert tells investors in a research note. Further, if Wesco does not succeed in acquiring Anixter, which is the more likely scenario, private equity has established an "appetite for distributors" which supports a takeout of Wesco, adds the analyst.
12/27/19
RAJA
12/27/19
NO CHANGE
RAJA
Strong Buy
Raymond James sees 'several positives' in Wesco revised proposal for Anixter
After Wesco (WCC) announced it had submitted a takeout offer of $93.50 per share in cash and stock for Anixter (AXE), Raymond James analyst Samuel Darkatsh said he had already assumed Wesco would raise its prior $90 offer but he sees "several positive takeaways" from Wesco's announcement compared to his prior assumptions regarding the deal, including higher than expected potential run-rate synergies of "greater than $200 million" and the fact that the transaction is not subject to a Wesco shareholder vote. Wesco seems intent on just acquiring Anixter and not selling itself, added Darkatsh, who called this "unsurprising." The analyst, who also noted that Wesco said its Q4 sales growth is trending above the consensus forecast, keeps a Strong Buy rating on Wesco shares.
TERP TerraForm Power
$15.60

0.085 (0.55%)

10/08/19
10/08/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Oracle (ORCL), Carbonite (CARB), and Check Point (CHKP) downgraded to Hold from Buy at Jefferies. 2. TerraForm Power (TERP) downgraded to Equal Weight from Overweight at Barclays. 3. Puma Biotechnology (PBYI) downgraded to Sell from Neutral at Goldman Sachs while Nektar Therapeutics (NKTR) was double downgraded to Sell from Buy. 4. Qiagen (QGEN) downgraded to Underweight from Neutral at JPMorgan and to Equal Weight from Overweight at Barclays. 5. Helmerich & Payne (HP) and Patterson-UTI (PTEN) downgraded to Neutral from Buy at BofA/Merrill. Nine Energy Services (NINE) and FTS International (FTSI) downgraded to Underperform from Neutral at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/08/19
LEHM
10/08/19
UPGRADE
Target $61
LEHM
Overweight
Barclays upgrades NextEra to Overweight, downgrades TerraForm to Equal Weight
Barclays analyst Moses Sutton upgraded NextEra Energy Partners (NEP) to Overweight from Equal Weight with a price target of $61, up from $52. NextEra Energy's underperformance relative to TerraForm Power (TERP) "has become a compelling opportunity," Sutton tells investors in a research note. At this point, from numerous perspectives, including price performance, relative yield, and 2020-2021 growth visibility, NextEra Energy screens as the best way to gain an outsized total return in the YieldCos group, contends the analyst. As a result, the analyst upgraded NextEra Energy Partners to Overweight and downgraded TerraForm Power to Equal Weight.
01/13/20
BMOC
01/13/20
UPGRADE
BMOC
Outperform
TerraForm Power upgraded to Outperform from Market Perform at BMO Capital
01/13/20
BMOC
01/13/20
UPGRADE
Target $18
BMOC
Outperform
TerraForm Power upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Ben Pham upgraded TerraForm Power to Outperform from Market Perform with a price target of $18, up from $17. The analyst cites the company's "unique" exposure to the solar sector with a "favorable" view of renewable power industry, along with the increased investor focus on ESG investing. Pham adds that his implied valuation multiple on TerraForm Power goes to 13-times from 12.5-times expected forward earnings.
BEP Brookfield Renewable
$48.04

-0.45 (-0.93%)

11/12/19
TDSI
11/12/19
DOWNGRADE
Target $45
TDSI
Hold
Brookfield Renewable downgraded to Hold from Buy at TD Securities
TD Securities analyst Sean Steuart downgraded Brookfield Renewable to Hold from Buy with a price target of $45, up from $43, after the company reported Q3 results that were near expectations and also confirmed its previously articulated plans to create an exchange corporation structure. Since late-December 2018, the stock has delivered total unitholder returns of 88%, assuming dividend reinvestment, and the units are now trading near the high-end of their historical valuation range, said Steuart.
07/11/19
LEHM
07/11/19
INITIATION
Target $40
LEHM
Overweight
Brookfield Renewable initiated with an Overweight at Barclays
Barclays analyst Moses Sutton started Brookfield Renewable Energy Partners with an Overweight rating and $40 price target. The analyst believes the company offers value as it lowers its payout ratio and accelerates ts distribution growth rate.
07/25/19
FBCO
07/25/19
DOWNGRADE
FBCO
Neutral
Brookfield Renewable downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Andrew Kuske downgraded Brookfield Renewable Partners to Neutral from Outperform citing the stock's recent performance as well as a reassessment of its "structural complexity."
07/04/19
BMOC
07/04/19
NO CHANGE
Target $35
BMOC
Market Perform
Brookfield Renewable target raised to $35 on X-Elio deal at BMO Capital
BMO Capital analyst Ben Pham raised his price target for Brookfield Renewable Partners to $35 from $34 following the company's acquisition of X-Elio. While the deal is "not massively accretive" near-term, it extends Brookfield Renewable's growth platform and improves visibility on its growth targets, Pham tells investors in a research note. The analyst reiterates a Market Perform rating on the shares.
HOME At Home Group
$5.09

-0.095 (-1.83%)

12/06/19
JEFF
12/06/19
DOWNGRADE
Target $6
JEFF
Hold
At Home Group downgraded to Hold at Jefferies until visibility improves
As previously reported, Jefferies analyst Jonathan Matuszewski downgraded At Home Group to Hold from Buy with a price target of $6, down from $7, following the company's mixed Q3 results and "disappointing" Q4 guidance. While its unique operating model has historically served At Home well, Matuszewski is concerned that in the near-term that will be overshadowed by intensifying competition and fact that the company has lagged in embracing the shift of home furnishings wallet share online. Until visibility improves, he prefers to move to the sidelines, added the analyst.
12/06/19
JEFF
12/06/19
DOWNGRADE
Target $6
JEFF
Hold
At Home Group downgraded to Hold from Buy at Jefferies
Jefferies analyst Jonathan Matuszewski downgraded At Home Group to Hold from Buy with a $6 price target.
12/05/19
12/05/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. F5 Networks (FFIV) double-downgraded to Underperform from Buy at BofA/Merrill with analyst Tal Liani warning about pressure on the company's revenue growth amid a "secular shift in demand from appliance-based Application Delivery Controllers to software and cloud-based solutions," which has weighed on pricing and also brought in competition from VMware (VMW), Amazon (AMZN), Google (GOOG) along with content delivery network providers like Akamai (AKAM). 2. Waters (WAT) downgraded to Neutral from Buy at BTIG with analyst Sun Ji Nam citing the 19% year-to-date run-up in the stock price and her lacking conviction on why the shares should trade at a premium relative to their peer group. 3. Etsy (ETSY) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Lauren Cassel saying her analysis indicates that headwinds from new state sales tax legislation and Etsy pulling back on its investment in Product Listing Ads could more than offset the benefits of free shipping. 4. At Home Group (HOME) downgraded to Market Perform from Outperform at William Blair with analyst Daniel Hofkin citing "limited visibility" following the company's guidance cut. 5. Discover (DFS) and Synchrony (SYF) were downgraded to Neutral from Buy at Nomura Instinet. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/05/19
WBLR
12/05/19
DOWNGRADE
WBLR
Market Perform
At Home Group downgraded to Market Perform on guidance cut at William Blair
William Blair analyst Daniel Hofkin downgraded At Home Group to Market Perform from Outperform citing "limited visibility" following the company's guidance cut. The company reduced its Q4 and full-year guidance substantially for comp sales, margins, and earnings, Hofkin tells investors in a research note. At Home Group slashed prices 25% in its Christmas assortment and also plans price cuts in furniture, the analyst adds. He believes that while the moves are intended to drive greater competitiveness and clear merchandise, they will "clearly pressure" both sales and margins, at least in the near term.
JILL J.Jill
$1.38

-0.01 (-0.72%)

12/06/19
JEFF
12/06/19
DOWNGRADE
Target $1.5
JEFF
Hold
Jefferies downgrades J.Jill to Hold, slashes price target to $1.50 from $5.00
Jefferies analyst Janine Stocher downgraded J.Jill to Hold from Buy with a price target of $1.50, down from $5.00, after the company reported lower than expected Q3 results, guided for its new quarter to come in well below consensus forecasts and announced CEO Linda Heasley is departing after less than two years. Stocher does not see signs of an imminent inflection at J.Jill and believes the CEO transition is likely to further delay a turn, she tells investors.
12/05/19
JEFF
12/05/19
DOWNGRADE
JEFF
Hold
J.Jill downgraded to Hold from Buy at Jefferies
Jefferies analyst Janine Stocher downgraded J.Jill to Hold from Buy.
05/31/19
DBAB
05/31/19
DOWNGRADE
Target $2
DBAB
Hold
Deutsche Bank downgrades J.Jill after 'ugly' guidance reduction
Deutsche Bank analyst Paul Trussell downgraded J.Jill to Hold from Buy and cut his price target for the shares to $2 from $9. The company's product assortment issues have led to conversion challenges, declining sales, and heavy inventory levels requiring significant markdowns, Trussell tells investors in a research note. He calls J.Jill's guidance reduction "ugly."
05/31/19
BOFA
05/31/19
DOWNGRADE
Target $2
BOFA
Neutral
BofA/Merrill downgrades J.Jill to Neutral, terminates coverage
BofA Merrill Lynch analyst Lorraine Hutchinson downgraded J. Jill to Neutral from Buy and lowered her price target on the stock to $2.00 from $8.50, stating that she expects the stock's multiple to contract due to the company's slower growth. Hutchinson also terminated coverage of the stock due to a reallocation of resources.
ABMD Abiomed
$188.93

5.2 (2.83%)

10/31/19
PIPR
10/31/19
NO CHANGE
Target $240
PIPR
Overweight
Abiomed Q2 results a 'relief,' guidance attainable, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien views Abiomed's Q2 results as a "relief" and keeps an Overweight rating on the shares with a $240 price target. Some investors may question the company's ability to meet the low end of its guidance given the large sequential increases factored in, O'Brien tells investors in a research note. However, he believes these levels "seem attainable" with the resurgence of RP, the 5.5 controlled rollout, and an expanded salesforce.
11/01/19
LEER
11/01/19
NO CHANGE
Target $240
LEER
Outperform
Abiomed price target raised to $240 from $195 at SVB Leerink
SVB Leerink analyst Danielle Antalffy raised her price target for Abiomed to $240 from $195 and maintained an Outperform rating following the company's "less-bad-than-feared" quarterly report. In a research note to investors, Antalffy says she believes fiscal 2020 guidance should be achievable, with further downside unlikely, but feels shares are likely to be range-bound into year-end.
11/19/19
JEFF
11/19/19
NO CHANGE
Target $255
JEFF
Buy
Abiomed 'dust storm around Impella' should settle over time, says Jefferies
Jefferies analyst Raj Denhoy said two presentations at the American Heart Association meeting suggest worse outcomes with Impella compared to intraortic balloon pumps, or IABP, but he contends that the studies "include several flaws and are at best more hypothesis-generating than anything definitive." Denhoy thinks the "dust storm around Impella" should linger but not persist, as he finds the AHA papers being in "stark contrast to reams of data" supporting the use of Impella and several studies showing IABP to have poor outcomes in these patients. The analyst, who concluded that his positive views on the longer-term opportunity for Abiomed and Impella are unchanged after the AHA meeting, keeps a Buy rating and $255 price target on the stock.
11/19/19
WBLR
11/19/19
NO CHANGE
WBLR
Outperform
New data 'another hurdle' Abiomed needs to overcome, says William Blair
Abiomed shares sold off 20% Monday after two retrospective, propensity-matched data sets were presented comparing the outcomes of the company's Impella and intra-aortic balloon pumps at the American Heart Association meeting on Sunday, William Blair analyst Margaret Kaczor tells investors in a research note. These data sets suggested that Impella, when compared to IABP, was associated with higher death and bleeding, did not improve clinical outcomes, and was a more costly treatment, explains the analyst. Kaczor does not think these data sets accurately capture the proper use of, and subsequently outcomes with, Impella, but she sees them as "likely another hurdle that Abiomed will need to overcome as it looks to reaccelerate adoption and utilization of its products." She continues to believe in Impella's "unique" clinical advantages and believes management is pursuing appropriate initiatives to drive long-term adoption and utilization of Impella. The analyst keeps an Outperform rating on the shares.
EXAS Exact Sciences
$104.60

1 (0.97%)

01/06/20
SBSH
01/06/20
INITIATION
Target $120
SBSH
Buy
Exact Sciences initiated with a Buy at Citi
Citi analyst Patrick Donnelly initiated coverage of Exact Sciences with a Buy rating and $120 price target.
01/10/20
BTIG
01/10/20
INITIATION
Target $127
BTIG
Buy
Exact Sciences assumed with a Buy at BTIG
BTIG analyst Amanda Murphy assumed coverage of Exact Sciences with a Buy rating and $127 price target. In a research note to investors, Murphy says she still sees meaningful room for growth in utilization of CRC screening. The analyst says market penetration of Cologuard is currently around 5%, and assumes Exact can get to 40% market penetration by 2030. Additionally, she says the acquisition of Genomic Health adds a key sales channel in oncology.
11/14/19
STFL
11/14/19
INITIATION
Target $110
STFL
Buy
Exact Sciences initiated with a Buy at Stifel
Stifel analyst Daniel Arias initiated coverage of Exact Sciences with a Buy rating and $110 price target. Cologuard momentum remains solid, with 2019 poised to finish with test volumes up 78%, Arias tells investors in a research note. He sees Exact as one of the highest quality names in the Diagnostics space. The risk/reward is skewed towards being long Exact Sciences shares into 2020, says the analyst.
12/13/19
DOTC
12/13/19
INITIATION
Target $120
DOTC
Buy
Exact Sciences initiated with a Buy at Dougherty
Dougherty initiated coverage of Exact Sciences with a Buy rating and $120 price target.
CHKP Check Point
$112.55

0.83 (0.74%)

01/13/20
MSCO
01/13/20
DOWNGRADE
Target $106
MSCO
Underweight
Check Point downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Keith Weiss downgraded Check Point Software to Underweight from Equal Weight with a $106 price target.
11/08/19
PIPR
11/08/19
INITIATION
Target $117
PIPR
Neutral
Check Point assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Rob Owens assumed coverage of Check Point Software with a Neutral rating and $117 price target.
01/13/20
MSCO
01/13/20
DOWNGRADE
Target $106
MSCO
Underweight
Check Point downgraded to Underweight on competitive pressures at Morgan Stanley
As previously reported, Morgan Stanley analyst Keith Weiss downgraded Check Point (CHKP) to Underweight from Equal Weight with a price target of $106, down from $115. His reseller andChief Security Officer surveys indicate Check Point's market share losses continue against network security competitors such as Palo Alto Networks (PANW) and Fortinet (FTNT), Weiss tells investors. Additionally, Check Point's sales execution challenges have yet to be remediated and Weiss expects investments, particularly in sales and marketing, to remain elevated in order to stem market share losses, the analyst added.
11/12/19
GSCO
11/12/19
INITIATION
Target $123
GSCO
Neutral
Check Point initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Brian Essex initiated coverage of Check Point Software with a Neutral rating and $123 price target. The analyst started the Security Software sector with an attractive view, believing IT Security offers "attractive levels of exposure to growth technology," and that profitable companies with this exposure could outperform the market. Essex says his latest reseller survey implies Check Point has "yet to turn the corner on execution." The company's "compelling" valuation is overshadowed by share losses, says the analyst.

TODAY'S FREE FLY STORIES

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.09

-0.18 (-4.22%)

16:40
01/17/20
01/17
16:40
01/17/20
16:40
Hot Stocks
Encana receives court approval for reorganization »

Encana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

MBRX

Moleculin Biotech

$0.96

0.0122 (1.29%)

16:38
01/17/20
01/17
16:38
01/17/20
16:38
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$20.07

-0.225 (-1.11%)

, BT

BT Group

$0.00

(0.00%)

16:37
01/17/20
01/17
16:37
01/17/20
16:37
Periodicals
BT, Vodafone consider urging PM Johnson not to ban Huawei in U.K., Reuters says »

BT Group (BT) and…

VOD

Vodafone

$20.07

-0.225 (-1.11%)

BT

BT Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/17/20
01/17
16:30
01/17/20
16:30
Options
Preliminary option volume of 28.7M today »

Preliminary option volume…

NSCO

Nesco Holdings

$5.12

0.025 (0.49%)

16:26
01/17/20
01/17
16:26
01/17/20
16:26
Syndicate
Nesco Holdings requests withdrawal of registration statement »

Nesco Holdings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$18.54

-0.075 (-0.40%)

, CMCSA

Comcast

$47.48

0.62 (1.32%)

16:20
01/17/20
01/17
16:20
01/17/20
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

The major averages were…

GPS

Gap

$18.54

-0.075 (-0.40%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

CMCSK

Comcast

$0.00

(0.00%)

PLAY

Dave & Buster's

$47.35

5.3 (12.60%)

KKR

KKR

$31.20

0.7 (2.30%)

BA

Boeing

$324.11

-7.89 (-2.38%)

JNJ

Johnson & Johnson

$149.07

0.82 (0.55%)

SWK

Stanley Black & Decker

$172.63

2.18 (1.28%)

TWOU

2U

$22.84

1.05 (4.82%)

BE

Bloom Energy

$9.70

0.43 (4.64%)

MGPI

MGP Ingredients

$38.16

-14.74 (-27.86%)

FAST

Fastenal

$36.77

-0.55 (-1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 20

    Jan

  • 22

    Jan

  • 23

    Jan

  • 29

    Jan

  • 29

    Jan

  • 31

    Jan

  • 26

    Feb

  • 27

    Feb

  • 09

    Mar

  • 17

    Mar

APLS

Apellis

$40.43

0.03 (0.07%)

16:18
01/17/20
01/17
16:18
01/17/20
16:18
Hot Stocks
Apellis CEO sells 30.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
01/17/20
01/17
16:17
01/17/20
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
01/17/20
01/17
16:16
01/17/20
16:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
01/17/20
01/17
16:15
01/17/20
16:15
General news
Treasury Market Summary »

Treasury Market Summary:…

LGC

Legacy Acquisition Corp

$10.33

(0.00%)

16:08
01/17/20
01/17
16:08
01/17/20
16:08
Hot Stocks
Legacy Acquisition Corp extends date to consummate proposed business combination »

Legacy Acquisition Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNUS

Genius Brands

$0.33

-0.015 (-4.41%)

16:04
01/17/20
01/17
16:04
01/17/20
16:04
Syndicate
Breaking Syndicate news story on Genius Brands »

Genius Brands files $50M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$90.21

1.28 (1.44%)

16:04
01/17/20
01/17
16:04
01/17/20
16:04
Periodicals
Best Buy board opens investigation into CEO's personal conduct, WSJ says »

The board of Best Buy is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.